Hany Elsheikha

Dr. Hany Elsheikha

University of Nottingham
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2017 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
QLQing Liu
Qing Liu
FLFa-Cai Li
Fa-Cai Li
HEHany Elsheikha
Hany Elsheikha
MSMiao-Miao Sun
Miao-Miao Sun
XZXing-Quan Zhu
Xing-Quan Zhu
Toxoplasma gondii, an obligate intracellular protozoan parasite, possesses the remarkable ability to co-opt host cell machinery in order to maintain its intracellular survival. This parasite can modulate signaling pathways of its host through the secretion of polymorphic effector proteins localized in the rhoptry and dense granule organelles. One of such effectors is T. gondii type II-specific dense granule protein 15, TgGRA15, which activates NF-κB pathway. The aim of the present study was to identify the host interaction partner proteins of TgGRA15. We screened a yeast two-hybrid mouse cDNA library using TgGRA15 as the bait. TgGRA15 (PRU strain, Type II) was cloned into the pGBKT7 vector and expressed in the Y2HGold yeast strain. Then, the bait protein expression was validated by western blotting analysis, followed by auto-activation and toxicity tests in comparison with control (Y2HGold yeast strain transformed with empty pGBKT7 vector). This screening led to the identification of mouse Luzp1 and AW209491 as host binding proteins that interact with TgGRA15. Luzp1 contains three nuclear localizing signals and is involved in regulating a subset of host non-coding RNA genes. These findings reveal, for the first time, new host cell proteins interacting with TgGRA15. The identification of these cellular targets and the understanding of their contribution to the host-pathogen interaction may serve as the foundation for novel therapeutic and prevention strategies against T. gondii infection.

16 December 2020 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
HEHany Elsheikha
Hany Elsheikha
CMChristina M. Marra
Christina M. Marra
XZXing-Quan Zhu
Xing-Quan Zhu
Toxoplasma gondiiis known to infect a considerable number of mammalian and avian species and a substantial proportion of the world’s human population. The parasite has an impressive ability to disseminate within the host’s body and employs various tactics to overcome the highly regulatory blood-brain barrier and reside in the brain. In healthy individuals,T. gondiiinfection is largely tolerated without any obvious ill effects. However, primary infection in immunosuppressed patients can result in acute cerebral or systemic disease, and reactivation of latent tissue cysts can lead to a deadly outcome.

13 June 2018 in Infectious Diseases of Poverty
Verified
Journal Article
Open access
PDF file
JCJia Chen
Jia Chen
QLQuan Liu
Quan Liu
GLGuo-Hua Liu
Guo-Hua Liu
WZWen-Bin Zheng
Wen-Bin Zheng
SHSung-Tae Hong
Sung-Tae Hong
HEHany Elsheikha
Hany Elsheikha
Toxocariasis is a neglected parasitic zoonosis that afflicts millions of the pediatric and adolescent populations worldwide, especially in impoverished communities. This disease is caused by infection with the larvae of Toxocara canis and T. cati, the most ubiquitous intestinal nematode parasite in dogs and cats, respectively. In this article, recent advances in the epidemiology, clinical presentation, diagnosis and pharmacotherapies that have been used in the treatment of toxocariasis are reviewed. Over the past two decades, we have come far in our understanding of the biology and epidemiology of toxocariasis. However, lack of laboratory infrastructure in some countries, lack of uniform case definitions and limited surveillance infrastructure are some of the challenges that hindered the estimation of global disease burden. Toxocariasis encompasses four clinical forms: visceral, ocular, covert and neural. Incorrect or misdiagnosis of any of these disabling conditions can result in severe health consequences and considerable medical care spending. Fortunately, multiple diagnostic modalities are available, which if effectively used together with the administration of appropriate pharmacologic therapies, can minimize any unnecessary patient morbidity. Although progress has been made in the management of toxocariasis patients, there remains much work to be done. Implementation of new technologies and better understanding of the pathogenesis of toxocariasis can identify new diagnostic biomarkers, which may help in increasing diagnostic accuracy. Also, further clinical research breakthroughs are needed to develop better ways to effectively control and prevent this serious disease.

1 April 2008 in Public Health
Verified
Journal Article
Closed access
HEHany Elsheikha
Hany Elsheikha

1 March 2019 in Trends in Parasitology
Verified
Journal Article
Closed access
JWJin-Lei Wang
Jin-Lei Wang
NZNian-Zhang Zhang
Nian-Zhang Zhang
TLTing-Ting Li
Ting-Ting Li
JHJun-Jun He
Jun-Jun He
HEHany Elsheikha
Hany Elsheikha
XZXing-Quan Zhu
Xing-Quan Zhu

1 March 2007 in Infection and Immunity
Verified
Journal Article
Closed access
Linda S. MansfieldLinda S. Mansfield
Linda S. Mansfield
JBJ. A. Bell
J. A. Bell
DWD. L. Wilson
D. L. Wilson
AMA. J. Murphy
A. J. Murphy
HEHany Elsheikha
Hany Elsheikha
VYV. B. Young
V. B. Young
Campylobacter jejuniis a globally distributed cause of human food-borne enteritis and has been linked to chronic joint and neurological diseases. We hypothesized thatC. jejuni11168 colonizes the gastrointestinal tract of both C57BL/6 mice and congenic C57BL/6 interleukin-10-deficient (IL-10−/−) mice and that C57BL/6 IL-10−/−mice experienceC. jejuni11168-mediated clinical signs and pathology. Individually housed mice were challenged orally withC. jejuni11168, and the course of infection was monitored by clinical examination, bacterial culture,C. jejuni-specific PCR, gross pathology, histopathology, immunohistochemistry, and anti-C. jejuni-specific serology. Ceca ofC. jejuni11168-infected mice were colonized at high rates: ceca of 50/50 wild-type mice and 168/170 IL-10−/−mice were colonized. In a range from 2 to 35 days after infection withC. jejuni11168, C57BL/6 IL-10−/−mice developed severe typhlocolitis best evaluated at the ileocecocolic junction. Rates of colonization and enteritis did not differ between male and female mice. A dose-response experiment showed that as little as 106CFU produced significant disease and pathological lesions similar to responses seen in humans. Immunohistochemical staining demonstratedC. jejuniantigens within gastrointestinal tissues of infected mice. Significant anti-C. jejuniplasma immunoglobulin levels developed by day 28 after infection in both wild-type and IL-10-deficient animals; antibodies were predominantly T-helper-cell 1 (Th1)-associated subtypes. These results indicate that the colonization of the mouse gastrointestinal tract byC. jejuni11168 is necessary but not sufficient for the development of enteritis and that C57BL/6 IL-10−/−mice can serve as models for the study ofC. jejunienteritis in humans.